Enter your keywords
HOME
About Us
NEWSLETTER
To search AlzRisk, use the "Keyword" search on the
AlzRisk search page
.
NEWS
All News
Conference Coverage
Series
WEBINARS
All Webinars
Databases
AlzBiomarker
AlzPedia
AlzRisk
Antibodies
Genetics
AlzGene
HEX
Mutations
Protocols
Research Models
Therapeutics
PAPERS
All Papers
Papers of the Week
Milestone
Alzforum Recommends
PROFESSIONAL RESOURCES
Conference Calendar
Grants
Jobs
Member Directory
ABOUT AD
AD Overview
Early-Onset Familial
The HBO Alzheimer's Project
Supported Browsers
MY ALZFORUM
My AlzForum Home
View Library
View Notifications
Set Notifications
Edit Profile
AlzRisk Paper Detail
Risk Factors
Alcohol
B Vitamins
Blood Pressure
Cognitive Activity
Diabetes Mellitus
Dietary Pattern
Head injury
Homocysteine
Hormone Therapy
Inflammatory Biomarkers
Non-Steroidal Anti-Inflammatory Drugs
Nutritional Antioxidants
Obesity
Physical Activity
Statin use
Reference:
Breitner, 2011
Cohort:
Adult Changes in Thought-Group Health Cooperative
Risk Factor:
Non-Steroidal Anti-Inflammatory Drugs
Exposure Detail
Investigators ascertained the exposure information via in-person interviews at baseline and at biennial follow-up visits. Information on prescriptions, such as drug name, strength, and amount dispensed, was collected. The number of standard daily doses (SDDs) associated with each prescription was calculated by multiplying the amount dispensed by the strength and then dividing by the SDD. The investigators reported results separately for dosage of any NSAID use via pharmacy dispensing data only and dosage of any NSAID use via pharmacy dispensing data integrated with self-report. This entry pertains to results on dosage of any NSAID use via pharmacy dispensing data only.
The investigators compared incident AD risk in three groups: the group of participants who had at least 500 SDD of any NSAIDs prescribed within two years ("Heavy use"), the group of participants who had in between 60-499 SDD of any NSAIDs prescribed within two years ("Moderate use"), and the reference group of participants who had less than 60 SDD of any NSAIDs prescribed within two years ("Light/no use").
Ethnicity Detail
The distribution of ethnicity among the "other" category was not specified.
Age Detail
The median age was 74.8 at enrollment.
Screening and Diagnosis Detail
Screening Method:
CASI
Cognitive Abilities Screening Instrument (Teng 1994)
Neuropsych Testing
AD Diagnosis:
NINCDS ADRDA
National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association Criteria (McKhann 1984)
Total Dementia Definition
: Dementia via DSM IV.
"Persons scoring ≤85 [on CASI] were referred for a dementia evaluation including neuropsychological testing, medical history, physical examination, laboratory testing, and appropriate neuroimaging. Diagnoses were assigned by a multidisciplinary study team at consensus conferences.
9
"
Covariates & Analysis Detail
Analysis Type:
Cox proportional hazards regression
Participant age was the time axis for the Cox proportional hazards models.
"Secondary analyses included not only pharmacy-based exposures but also self-reports of NSAID use. For the self-report analyses only, heavy use of NSAIDs required a report of use on two or more successive visits. Again, exposure status over time reflected the highest category to date, whether from pharmacy or self-report data."
AD Covariates:
A
age
E
education
G
gender
APOE4
APOE e4 genotype
BMI
body mass index
DM
diabetes mellitus
HTN
hypertension
OA
Osteoarthritis
PA
physical activity
SP
study population
TD Covariates:
A
age
E
education
G
gender
APOE4
APOE e4 genotype
BMI
body mass index
DM
diabetes mellitus
HTN
hypertension
OA
Osteoarthritis
PA
physical activity
SP
study population